LONSURF (TRIFLURIDINE/TIPIRACIL HCL)
- Metastatic colorectal cancer
- Metastatic gastric cancer
15 mg-6.14 mg tablet
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle max 80 mg/dose based on trifluridine
20 mg-8.19 mg tablet
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle max 80 mg/dose based on trifluridine
Metastatic colorectal cancer
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 of a 28 day cycle max of 80 mg/dose based on trifluridine component
- 35 mg/m2 by oral route 2 times per day on days 8 through 12 of a28 day cycle max of 80 mg/dose based on trifluridine component
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle max 80 mg/dose based on trifluridine
- 3 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 3 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 3 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
- 4 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 4 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 4 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
- 2 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 2 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 2 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
Metastatic gastric cancer
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 of a 28 day cycle max of 80 mg/dose based on trifluridine component
- 35 mg/m2 by oral route 2 times per day on days 8 through 12 of a28 day cycle max of 80 mg/dose based on trifluridine component
- 35 mg/m2 by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle max 80 mg/dose based on trifluridine
- 3 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 3 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 3 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
- 4 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 4 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 4 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
- 2 tablets by oral route 2 times per day on days 1 through 5 of a28 day cycle
- 2 tablets by oral route 2 times per day on days 8 through 12 of a 28 day cycle
- 2 tablets by oral route 2 times per day on days 1 through 5 and days 8 through 12 of a 28 day cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Severe hepatic disease
Contraindicated
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Anemia
LONSURF (TRIFLURIDINE/TIPIRACIL HCL)
- Metastatic colorectal cancer
- Metastatic gastric cancer
- Anemia
- Neutropenic disorder
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Diarrhea
- Fatigue
- Fever
- General weakness
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Alopecia
- Dysgeusia
- Pharyngitis
- Stomatitis
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Interstitial lung disease
- Pulmonary thromboembolism
Less Severe
- None
Contraindicated
None
Severe Precaution
Trifluridine, Tipiracil
Potential risk of dental toxicity. Safety and efficacy not established.
- 1 Day – 18 Years
- Potential risk of dental toxicity. Safety and efficacy not established.
Management or Monitoring Precaution
None
Trifluridine-tipiracil
- Severity Level:
D
- Additional Notes: Based on pharmacology and animal data potential for dev tox
Contraindicated
Trifluridine- Tipiracil
Insuff human data avail; based on pharmacology, potential for adv effects
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data avail; based on pharmacology, potential for adv effects |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Trifluridine And Tipiracil
General-Grade 3 or 4 neutropenia and thrombocytopenia, and Grade 3 anemia occurred more commonly in patients 65 years old or older. Renal-Though no baseline dose adjustment is required for CrCL 30-89 mL/min, there was an increased incidence of grade 3 toxicities that may require dose adjustment.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
Metastatic colorectal cancer | |
C18 | Malignant neoplasm of colon |
C18.0 | Malignant neoplasm of cecum |
C18.1 | Malignant neoplasm of appendix |
C18.2 | Malignant neoplasm of ascending colon |
C18.3 | Malignant neoplasm of hepatic flexure |
C18.4 | Malignant neoplasm of transverse colon |
C18.5 | Malignant neoplasm of splenic flexure |
C18.6 | Malignant neoplasm of descending colon |
C18.7 | Malignant neoplasm of sigmoid colon |
C18.8 | Malignant neoplasm of overlapping sites of colon |
C18.9 | Malignant neoplasm of colon, unspecified |
C19 | Malignant neoplasm of rectosigmoid junction |
C20 | Malignant neoplasm of rectum |
C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
Metastatic gastric cancer | |
C16 | Malignant neoplasm of stomach |
C16.0 | Malignant neoplasm of cardia |
C16.1 | Malignant neoplasm of fundus of stomach |
C16.2 | Malignant neoplasm of body of stomach |
C16.3 | Malignant neoplasm of pyloric antrum |
C16.4 | Malignant neoplasm of pylorus |
C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
C16.8 | Malignant neoplasm of overlapping sites of stomach |
C16.9 | Malignant neoplasm of stomach, unspecified |
0-9 | A-Z |
---|---|
C16 | Malignant neoplasm of stomach |
C16.0 | Malignant neoplasm of cardia |
C16.1 | Malignant neoplasm of fundus of stomach |
C16.2 | Malignant neoplasm of body of stomach |
C16.3 | Malignant neoplasm of pyloric antrum |
C16.4 | Malignant neoplasm of pylorus |
C16.5 | Malignant neoplasm of lesser curvature of stomach, unspecified |
C16.6 | Malignant neoplasm of greater curvature of stomach, unspecified |
C16.8 | Malignant neoplasm of overlapping sites of stomach |
C16.9 | Malignant neoplasm of stomach, unspecified |
C18 | Malignant neoplasm of colon |
C18.0 | Malignant neoplasm of cecum |
C18.1 | Malignant neoplasm of appendix |
C18.2 | Malignant neoplasm of ascending colon |
C18.3 | Malignant neoplasm of hepatic flexure |
C18.4 | Malignant neoplasm of transverse colon |
C18.5 | Malignant neoplasm of splenic flexure |
C18.6 | Malignant neoplasm of descending colon |
C18.7 | Malignant neoplasm of sigmoid colon |
C18.8 | Malignant neoplasm of overlapping sites of colon |
C18.9 | Malignant neoplasm of colon, unspecified |
C19 | Malignant neoplasm of rectosigmoid junction |
C20 | Malignant neoplasm of rectum |
C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |